COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
COVID-19 vaccine
Federal Bureau of Prisons
SARS-CoV-2
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 09 2021
24 09 2021
Historique:
received:
13
07
2021
revised:
10
08
2021
accepted:
11
08
2021
pubmed:
2
9
2021
medline:
24
9
2021
entrez:
1
9
2021
Statut:
ppublish
Résumé
To describe COVID-19 vaccine distribution operations in United States Federal Bureau of Prisons (BOP) institutions and offices from December 16, 2020-April 14, 2021, report vaccination coverage among staff and incarcerated people, and identify factors associated with vaccination acceptance among incarcerated people. The BOP COVID-19 vaccination plan and implementation timeline are described. Descriptive statistics and vaccination coverage were calculated for the BOP incarcerated population using data from the BOP electronic medical record. Coverage among staff was calculated using data from the Centers for Disease Control and Prevention Vaccination Administration Management System. Vaccination coverage in the BOP versus the overall United States adult population was compared by state/territory. Univariate and multivariable logistic regression models were developed to identify demographic, health-related, and institution-level factors associated with vaccination acceptance among incarcerated people, using hierarchical linear modeling to account for institution-level clustering. By April 14, 2021, BOP had offered COVID-19 vaccination to 37,870 (100%) staff and 88,173/126,413 (69.8%) incarcerated people, with acceptance rates of 50.2% and 64.2%, respectively. At the time of analysis, vaccination coverage in BOP was comparable to coverage in the overall adult population in the states and territories where BOP institutions and offices are located. Among incarcerated people, factors associated with lower vaccination acceptance included younger age, female sex, non-Hispanic Black and Asian race/ethnicity, and having few underlying medical conditions; factors associated with higher acceptance included having a prior SARS-CoV-2 infection, being born outside the United States, and being assigned to a Federal Detention Center. Early COVID-19 vaccination efforts in BOP have achieved levels of coverage similar to the general population. To build on this initial success, BOP can consider strategies including re-offering vaccination to people who initially refused and tailoring communication strategies to groups with lower acceptance rates.
Identifiants
pubmed: 34465473
pii: S0264-410X(21)01078-1
doi: 10.1016/j.vaccine.2021.08.045
pmc: PMC8363472
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5883-5890Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1139-1143
pubmed: 32817597
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):217-222
pubmed: 33571174
J Natl Med Assoc. 2021 Feb;113(1):6-7
pubmed: 33583497
JAMA. 2020 Dec 29;:
pubmed: 33372943
Am J Public Health. 2021 Jun;111(6):1164-1167
pubmed: 33856883
Harm Reduct J. 2019 Jul 5;16(1):42
pubmed: 31277665
Am J Prev Med. 2021 Jul;61(1):120-123
pubmed: 33781619
J Health Care Poor Underserved. 2018;29(4):1544-1557
pubmed: 30449762
N Engl J Med. 2021 Jul 22;385(4):374-376
pubmed: 33979505
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):473-477
pubmed: 33793457